Apheon, a leading European private equity firm, is pleased to announce that it has entered into exclusive negotiations to acquire a majority stake in Teknimed (“the Company”), a leading independent manufacturer of orthopaedic bone cements and biomaterials worldwide. Through this transaction, Apheon will succeed Essling Capital and partner with Carole Léonard, Teknimed’s CEO and second-generation family owner, who will remain a significant shareholder alongside Apheon.
Headquartered in Toulouse, France, and founded in 1990, Teknimed develops, manufactures and distributes arthroplasty and spinal cements, synthetic bone substitutes, sports medicine solutions and other biomaterials used across a broad range of orthopaedic and surgical applications. Teknimed operates a fully integrated business model spanning in-house formulation, product development, manufacturing and distribution. The Company’s strong scientific capabilities, deep clinical expertise and long-standing regulatory excellence have enabled it to build a reputation for innovation, quality and reliability. Reflecting its commitment to the highest standards of patient safety and product performance, Teknimed’s entire product portfolio is MDR-certified. Since its foundation, Teknimed has grown into a leading biomaterials platform serving approximately 280 OEMs and distributors in more than 80 countries.
Under Carole Léonard’s leadership, Teknimed has delivered an exceptional growth trajectory, doubling its revenue in recent years while consistently outperforming its underlying markets. The Company has further solidified its position as a trusted partner to leading orthopaedic OEMs and distributors globally, supported by its outstanding product quality, extensive clinical track record and operational excellence.
The partnership with Apheon marks a new phase of growth for Teknimed. Leveraging Apheon’s track record in healthcare investing and international expansion, the Company plans to accelerate its global development, strengthen its biomaterials platform and broaden its product offering. Teknimed also intends to pursue strategic acquisitions to complement its strong organic growth, expand its portfolio and deepen its presence in key international markets.
The proposed transaction will be shortly submitted to the consultation of the employee representatives and would remain subject to customary regulatory approvals and conditions.
Carole Léonard, CEO of Teknimed, commented: "In recent years, Teknimed has evolved into a recognised leader in biomaterials, driven by our unwavering commitment to scientific excellence, product quality and patient outcomes. As we look ahead, we see significant opportunities to bring our technologies and expertise to an even broader customer and patient base worldwide. In Apheon, we have found a partner who shares our long-term vision and brings the capital, strategic support and M&A expertise needed to accelerate our development. Together, we will solidify our position as a leading global biomaterials platform while upholding the scientific standards and patient focus that define this company."
Wolfgang de Limburg, Managing Partner of Apheon, added: "Teknimed is an exceptional business – exactly the kind of platform Apheon was built to support. We have tremendous respect for Carole and her team, who have created a unique company combining deep biomaterials expertise, strong regulatory capabilities and trusted relationships with leading orthopaedic OEMs and distributors worldwide. We would be delighted to partner with Carole and the entire Teknimed team and embark on this next chapter together, with the shared ambition of building a global leader in biomaterials."
About Teknimed
Teknimed is a French medtech company specialising in orthopaedic bone cements and biomaterials. Founded in 1990 and headquartered in Toulouse, the Company develops, manufactures and distributes arthroplasty and spinal cements, synthetic bone substitutes, sports medicine solutions and other biomaterials. Teknimed serves approximately 280 customers in more than 80 countries and operates a vertically integrated model from in-house formulation through to finished products. For more information, please visit www.teknimed.com.
About Apheon
Apheon is a pan-European mid-market private equity investment company managing ~€4.5 billion of assets from select global institutional investors and families. Apheon is characterized by its partnership approach, providing “patient and friendly capital” and industrial know-how to entrepreneurs and management teams, preparing their companies for the future. Through its pan-European footprint, the firm acts as a gateway into Europe for companies in the mid-market. Since its founding in 2005, Apheon has raised more than €5 billion in capital, invested in ~45 companies across Europe and completed ~250 add-on acquisitions for a total aggregate transaction value in excess of €8 billion. Apheon’s current portfolio consists of ~25 companies across its target sectors, representing ~€3.5 billion sales and more than 20,000 employees. Apheon is advised by Apheon Advisors, which has offices in Brussels, Milan, Madrid, Paris, Munich and Amsterdam. For more information, please visit www.apheon.com.
+++
For more information, please contact:
John Mansvelt, COO, Apheon
jm@apheon.com
T: +32 2 213 60 90
Natalia Yek, Head of Investor Relations, Apheon
ny@apheon.com
T: +32 2 213 60 90
Our manifesto: contributing to the development of sustainable finance
To succeed with this strategy, Apheon believes a holistic and collective approach is fundamental.
Holistic: it is essential that all aspects of ESG are equally and continuously supported. This is why we are active at every stage of the investment cycle by applying proprietarily developed methodologies and initiatives which are built on 5 priorities covering the broad ESG spectrum: